Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Pancreatic Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Pancreatic Ductal Adenocarcinoma (117
)
Pancreatic Adenocarcinoma (64
)
Pancreatic Ductal Adenocarcinoma (117
)
Pancreatic Adenocarcinoma (64
)
›
Associations
(407)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
IL1RAP overexpression
Pancreatic Ductal Adenocarcinoma
IL1RAP overexpression
Pancreatic Ductal Adenocarcinoma
CAN04
Sensitive: C3 – Early Trials
AACR 2023 - 5 days (New C3)
CAN04
Sensitive
:
C3
AACR 2023 - 5d
CAN04
Sensitive: C3 – Early Trials
AACR 2023 - 5 days
CAN04
Sensitive
:
C3
AACR 2023 - 5 days - (New C3)
MTAP deletion
Pancreatic Cancer
MTAP deletion
Pancreatic Cancer
IDE397
Sensitive: D – Preclinical
AACR 2023 - 5 days (New D)
IDE397
Sensitive
:
D
AACR 2023 - 5d
IDE397
Sensitive: D – Preclinical
AACR 2023 - 5 days
IDE397
Sensitive
:
D
AACR 2023 - 5 days - (New D)
KRAS Q61H
Pancreatic Ductal Adenocarcinoma
KRAS Q61H
Pancreatic Ductal Adenocarcinoma
RM-046
Sensitive: D – Preclinical
AACR 2023 - 5 days (New D)
RM-046
Sensitive
:
D
AACR 2023 - 5d
RM-046
Sensitive: D – Preclinical
AACR 2023 - 5 days
RM-046
Sensitive
:
D
AACR 2023 - 5 days - (New D)
KRAS G12C
Pancreatic Cancer
KRAS G12C
Pancreatic Cancer
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 5 days (New D)
ZG19018
Sensitive
:
D
AACR 2023 - 5d
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 5 days
ZG19018
Sensitive
:
D
AACR 2023 - 5 days - (New D)
KRAS mutation
Pancreatic Cancer
KRAS mutation
Pancreatic Cancer
RGT-018
Sensitive: D – Preclinical
AACR 2023 - 5 days (New D)
RGT-018
Sensitive
:
D
AACR 2023 - 5d
RGT-018
Sensitive: D – Preclinical
AACR 2023 - 5 days
RGT-018
Sensitive
:
D
AACR 2023 - 5 days - (New D)
KRAS G12D
Pancreatic Ductal Adenocarcinoma
KRAS G12D
Pancreatic Ductal Adenocarcinoma
RMC-9805
Sensitive: D – Preclinical
AACR 2023 - 5 days (New D)
RMC-9805
Sensitive
:
D
AACR 2023 - 5d
RMC-9805
Sensitive: D – Preclinical
AACR 2023 - 5 days
RMC-9805
Sensitive
:
D
AACR 2023 - 5 days - (New D)
HRD
Pancreatic Ductal Adenocarcinoma
HRD
Pancreatic Ductal Adenocarcinoma
JPI-547
Sensitive: D – Preclinical
AACR 2023 - 5 days (New D)
JPI-547
Sensitive
:
D
AACR 2023 - 5d
JPI-547
Sensitive: D – Preclinical
AACR 2023 - 5 days
JPI-547
Sensitive
:
D
AACR 2023 - 5 days - (New D)
RNF43 mutation
Pancreatic Ductal Adenocarcinoma
RNF43 mutation
Pancreatic Ductal Adenocarcinoma
JPI-547
Sensitive: D – Preclinical
AACR 2023 - 5 days (New D)
JPI-547
Sensitive
:
D
AACR 2023 - 5d
JPI-547
Sensitive: D – Preclinical
AACR 2023 - 5 days
JPI-547
Sensitive
:
D
AACR 2023 - 5 days - (New D)
CLDN18.2 expression
Pancreatic Cancer
CLDN18.2 expression
Pancreatic Cancer
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks (New D)
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2wk
SOT102
Sensitive: D – Preclinical
ESMO-TAT 2023 - 2 weeks
SOT102
Sensitive
:
D
ESMO-TAT 2023 - 2 weeks - (New D)
BRCA2 mutation
Pancreatic Cancer
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
C1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
C1
BRCA1 mutation
Pancreatic Cancer
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
C1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
C1
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive: A1 - Approval
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive
:
A1
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive: A1 - Approval
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive
:
A1
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
erlotinib
Sensitive: A1 - Approval
erlotinib
Sensitive
:
A1
erlotinib
Sensitive: A1 - Approval
erlotinib
Sensitive
:
A1
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
GEM-CAP
Sensitive: A2 - Guideline
GEM-CAP
Sensitive
:
A2
GEM-CAP
Sensitive: A2 - Guideline
GEM-CAP
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
LV5FU2
Sensitive: A2 - Guideline
LV5FU2
Sensitive
:
A2
LV5FU2
Sensitive: A2 - Guideline
LV5FU2
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
NTRK3 fusion
Pancreatic Adenocarcinoma
NTRK3 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Pancreatic Adenocarcinoma
NTRK2 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Adenocarcinoma
NTRK1 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
5-fluorouracil + nanoliposomal irinotecan
Sensitive: A2 - Guideline
5-fluorouracil + nanoliposomal irinotecan
Sensitive
:
A2
5-fluorouracil + nanoliposomal irinotecan
Sensitive: A2 - Guideline
5-fluorouracil + nanoliposomal irinotecan
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
5-fluorouracil + irinotecan
Sensitive
:
A2
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
5-fluorouracil + irinotecan
Sensitive
:
A2
NTRK3 fusion
Pancreatic Adenocarcinoma
NTRK3 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
erlotinib
Sensitive: A2 - Guideline
erlotinib
Sensitive
:
A2
erlotinib
Sensitive: A2 - Guideline
erlotinib
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + capecitabine
Sensitive: A2 - Guideline
5-fluorouracil + capecitabine
Sensitive
:
A2
5-fluorouracil + capecitabine
Sensitive: A2 - Guideline
5-fluorouracil + capecitabine
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + capecitabine
Sensitive: A2 - Guideline
gemcitabine + capecitabine
Sensitive
:
A2
gemcitabine + capecitabine
Sensitive: A2 - Guideline
gemcitabine + capecitabine
Sensitive
:
A2
BRCA1 mutation
Pancreatic Adenocarcinoma
BRCA1 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
BRCA2 mutation
Pancreatic Adenocarcinoma
BRCA2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
PALB2 mutation
Pancreatic Adenocarcinoma
PALB2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
FOLFIRINOX
Sensitive: A2 - Guideline
FOLFIRINOX
Sensitive
:
A2
FOLFIRINOX
Sensitive: A2 - Guideline
FOLFIRINOX
Sensitive
:
A2
No biomarker
Pancreatic Cancer
No biomarker
Pancreatic Cancer
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
NTRK3 fusion
Pancreatic Cancer
NTRK3 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Pancreatic Cancer
NTRK2 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Pancreatic Cancer
NTRK1 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Pancreatic Cancer
NTRK3 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login